Absci, a pioneering biotech company focused on advancing therapeutics through generative AI, has recently unveiled a groundbreaking collaboration with Oracle Cloud Infrastructure (OCI) and AMD. This strategic partnership aims to revolutionize the drug discovery process by harnessing the power of cutting-edge technologies. By integrating Absci’s generative AI Drug Creation Platform with OCI’s AI infrastructure and AMD’s advanced hardware, the company seeks to accelerate biologics design cycles and bring novel therapeutics to patients more efficiently.
The selection of OCI as the technical backbone for developing AI models and scaling AI workflows underscores Absci’s commitment to leveraging state-of-the-art resources. Through OCI, Absci has streamlined the development and operations of its AI Drug Creation Platform, enabling activities such as large-scale molecular dynamics simulations and end-to-end antibody design. Building upon this foundation, Absci has joined forces with AMD to enhance the performance and scalability of its platform using AMD’s next-generation Instinct™ MI355X GPUs.
Sean McClain, the Founder and CEO of Absci, expressed enthusiasm about the collaboration, emphasizing the company’s dedication to pushing the boundaries of therapeutic design. By combining their advanced AI models with OCI and AMD’s infrastructure, Absci aims to accelerate the delivery of innovative therapeutics while establishing a robust technical framework for future AI-powered drug discovery workflows.
OCI’s bare metal instances, featuring 5th Generation AMD EPYC™ processors and high-speed RDMA cluster networking, provide Absci with the essential low-latency networking and throughput capabilities required for complex model training and molecular dynamics simulations. Direct access to AMD GPUs within a flat-network supercluster environment has enabled Absci to optimize performance by minimizing overhead and latency, facilitating terabytes-per-second throughput for critical processes like checkpointing and data streaming.
Dan Spellman, Vice President of AI and OCI in Healthcare & Life Sciences at Oracle, highlighted Absci’s groundbreaking approach to AI-driven drug discovery, citing the seamless integration of GPU resources, ultrafast networking, and high-performance storage within OCI’s ecosystem. This comprehensive support ensures that Absci can continue to innovate in biologics design with enhanced predictability and engineering collaboration.
Ram Peddibhotla, Corporate Vice President of Data Center GPU Cloud Business at AMD, commended Absci’s commitment to leveraging AI for accelerated drug discovery. The collaboration’s utilization of OCI, AMD EPYC CPUs, Instinct GPUs, and the open ROCm software platform reflects a shared vision for advancing biologics design through heightened performance and scalability.
In a landscape where precision and efficiency are paramount in drug discovery, Absci’s collaboration with Oracle and AMD signifies a significant step towards harnessing the full potential of AI-driven platforms. By combining cutting-edge technologies with strategic partnerships, Absci is poised to revolutionize the pharmaceutical industry and pave the way for more effective and streamlined drug development processes.
- Leveraging advanced AI platforms through collaborations with industry leaders like Oracle and AMD can significantly enhance drug discovery processes.
- The integration of OCI’s AI infrastructure and AMD’s hardware with Absci’s generative AI Drug Creation Platform showcases a commitment to innovation and efficiency in therapeutic design.
- Direct access to high-performance resources such as AMD GPUs and ultrafast networking within OCI’s ecosystem empowers Absci to optimize critical processes and accelerate biologics development.
Tags: biotech
Read more on insidehpc.com